vimarsana.com

Page 57 - ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021

MD Anderson advances data collaboration through technology agreement with Syntropy

Jaguar Health, Inc : Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Mee

(0) SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ( CTD ) by Napo Pharmaceuticals, Inc. ( Napo ), Jaguar s wholly owned subsidiary, and Napo s collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO ®) Annual Meeting, which will be held virtually from June 4-8, 2021. The title of the accepted poster presentation is: The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence Poster Session: Symptoms and Survivorship The lead author of the study is Pablo C. Okhuysen, MD. Dr. Okhuysen is Professor of Medicine, Department of Infectious Diseases, Infection Control, and Employee Health, Division of Internal Medicine, at the University of Texas, MD Anderson Cancer Center in Houston, Texas. Additional authors include Lee Schwartzberg, MD, F

MD Anderson response to FDA proposal to prohibit menthol cigarettes

Soliton Receives FDA Clearance of Special 510(k)

Soliton Receives FDA Clearance of Special 510(k) Notification paves way for second quarter commercial launch News provided by Share this article Share this article HOUSTON, April 29, 2021 /PRNewswire/  Soliton, Inc., (Nasdaq: SOLY) ( Soliton or the Company ), a medical device company with a novel and proprietary platform technology, today announced the U.S. Food and Drug Administration ( FDA ) clearance of the Company s special 510(k) for modifications to its RESONIC™ device. We were thrilled to receive this clearance as it marks the last significant hurdle to our ability to initiate our commercial launch of the improved RESONIC device in the second quarter, stated Brad Hauser, Soliton CEO and President. Our discussions with our target dermatologists and plastic surgeons on our Rapid Acoustic Pulse (RAP) technology have been very well received and there is strong enthusiasm for an effective and efficient patient experience for tattoo removal and cellulite treatment wi

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.